Capecitabine and Hand-foot Syndrome: A Case Report.

Autor:	Uppala PK; Santhiram Medical College, Nandyal, Andhra Pradesh, India., Varghese AM; Department of Pharmacology, Santhiram Medical College, Nandyal, Andhra Pradesh, India., Yella SST; Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India., Velmurugan H; Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India., Thangaraju P; Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India., Krishna Sasanka KSBS; Department of ENT, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
Jazyk:	angličtina
Zdroj:	Infectious disorders drug targets [Infect Disord Drug Targets] 2023; Vol. 23 (1), pp. e140622205973.
DOI:	10.2174/1871526522666220614162117
Abstrakt:	Capecitabine, a prodrug of 5-fluorouracil, is an FDA-approved drug for adjuvant treatment of colon, metastatic colorectal, and breast cancer. A variety of mucocutaneous adverse effects has been recognized with capecitabine. The pathogenesis of such manifestations still remains an enigma though various theories have been proposed. Here, we report two such cases. A 59-year-old female with carcinoma of the sigmoid colon on palliative therapy developed localized cutaneous hyperpigmentation of the palms and soles secondary to capecitabine in her 2nd cycle. Another case was of a 42-year-old female with stomach adenocarcinoma, who developed similar adverse effects after administration of capecitabine in her 4th cycle. Since these drugs have been widely used in recent years due to their relative ease in administration, the relative unawareness of Hand-foot syndrome (HFS) caused due to this drug makes it a prudent topic to be reported. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu